

is superior in stability and oral absorbability compared to the Form I crystal, thereby completing the present invention.

[0008]

Thus, the present invention relates to provision of the following [1] to [15].

[0009]

[1] A Form II crystal of 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide showing an X-ray powder diffraction spectrum having at least three characteristic diffraction peaks at angles ($2\theta \pm 0.2^\circ$) selected from the group consisting of 7.7° , 8.0° , 11.1° , 12.5° , 12.9° , 15.2° , 15.8° , 17.2° , 19.0° , 22.5° , 26.1° , and 27.4° .

[2] The Form II crystal according to [1], wherein the crystal shows an X-ray powder diffraction spectrum having at least five characteristic diffraction peaks at angles ($2\theta \pm 0.2^\circ$) selected from the group consisting of 7.7° , 8.0° , 11.1° , 12.5° , 12.9° , 15.2° , 15.8° , 17.2° , 19.0° , 22.5° , 26.1° , and 27.4° .

[3] The Form II crystal according to [1] or [2], wherein the endothermic peak determined by differential scanning calorimetry is around 270°C .

[4] A pharmaceutical composition comprising the Form II crystal according to any of [1] to [3].

[5] A pharmaceutical composition for oral administration comprising the Form II crystal according to any of [1] to [3].

[6] An antitumor agent comprising the Form II crystal according to any of [1] to [3].

[7] Use of the Form II crystal according to any of [1] to [3], for the production of a pharmaceutical composition.

[8] The use according to [7], wherein the pharmaceutical composition is a pharmaceutical composition for oral administration.